Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing PI4KIIIα Levels or Activity Limits Tau Seed Internalization and Assembly in Human Cortical Neurons.

Cells·2026
Same author

Clickable Substrate Transport (CST): A High-Throughput Functional Assay for Solute Carrier Proteins.

ACS chemical biology·2026
Same author

B cell-derived type I interferon sustains T cell functionality upon strong TCR stimulation during chronic infection.

Immunity·2026
Same author

AURORA A interacts with DICER and SETD2 to promote S-phase progression.

EMBO reports·2026
Same author

Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling.

iScience·2026
Same author

Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis.

Nature communications·2026

Related Experiment Video

Updated: Sep 25, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing

Jonas Lategahn1,2,3, Hannah L Tumbrink4,5, Carsten Schultz-Fademrecht1,6

  • 1PearlRiver Bio GmbH, Otto-Hahn-Str. 15, 44227 Dortmund, Germany.

Journal of Medicinal Chemistry
|April 29, 2022
PubMed
Summary

Novel covalent inhibitors targeting EGFR and Her2 exon20 insertion mutations in non-small cell lung cancer show promise. These pyrrolopyridine compounds effectively inhibited mutant forms, leading to tumor shrinkage in preclinical models.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Experiment Videos

Last Updated: Sep 25, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Non-small cell lung cancer (NSCLC) with EGFR/Her2 exon20 insertion mutations presents limited therapeutic options.
  • Epidermal growth factor receptor (EGFR) inhibitors are effective but a subset of NSCLC patients harbors specific mutations.
  • Exon20 insertion mutations in EGFR and Her2 confer resistance to existing targeted therapies.

Purpose of the Study:

  • To develop and characterize novel covalent inhibitors targeting EGFR and Her2 exon20 insertion mutations.
  • To evaluate the inhibitory potency and selectivity of new compounds against mutant EGFR and Her2.
  • To assess the in vivo efficacy of developed inhibitors in patient-derived xenograft models.

Main Methods:

  • Design and synthesis of novel covalent inhibitors based on a 1H-pyrrolo[2,3-b]pyridine scaffold.
  • Biochemical and cellular assays to determine inhibitory potency against wild-type and mutant EGFR/Her2.
  • X-ray crystallography to elucidate inhibitor-target binding interactions.
  • In vivo efficacy studies using patient-derived xenografts with EGFR exon20 insertion mutations.

Main Results:

  • Developed novel covalent inhibitors LDC8201 and LDC0496 with potent activity against EGFR and Her2 exon20 insertion mutations.
  • Demonstrated high selectivity for mutant EGFR/Her2 over wild-type EGFR and other kinases.
  • Confirmed favorable binding characteristics through complex crystal structures and biochemical data.
  • Observed significant tumor shrinkage in mice treated with LDC8201 harboring patient-derived EGFR mutant cells.

Conclusions:

  • Covalent pyrrolopyridines represent a promising class of inhibitors for targeting EGFR/Her2 exon20 insertion mutations in NSCLC.
  • LDC8201 and LDC0496 show potential as effective therapeutic agents for patients with limited treatment options.
  • Further development of these inhibitors could address unmet needs in NSCLC treatment.